Entresto Hurdles Dog Novartis
This article was originally published in Scrip
Entresto's slow market start following its US approval prompted many questions as Novartis AG reported its quarterly results Oct. 27. The heart failure drug booked sales of $16m in third quarter following FDA approval on July 7, 2015, and the company acknowledged that its current lack of reimbursement status for Medicare Part D patients – which make up a large part of its target population – was holding it back. By way of contrast, sales for psoriasis drug Cosentyx (secukinumab), which was approved in the US in January, were $88m in the third quarter.